Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Regorafenib is an oral medication that can interfere with cancer cell growth and reduce the
growth of blood vessels around tumors. This study will help find out if regorafenib is a
useful drug for treating patients with adenoid cystic carcinomas. Regorafenib has been
approved by the Food and Drug Administration (FDA) for use in other cancers, but remains an
experimental drug that has not yet been approved for use in adenoid cystic carcinoma.
In this study, the patient will initially be treated with a dose of regorafenib that is lower
than what the FDA approved for other cancers in an attempt to decrease the risk of side
effects. It is possible that this lower starting dose may not be as effective as the higher
FDA approved dose. If the patient does well with the lower dose for at least a month on
treatment, the physician may consider increasing the dose to the FDA approved dose.